---
figid: PMC8576142__gr3_lrg
figtitle: Myeloid dysregulation and therapeutic intervention in COVID-19
organisms:
- Severe acute respiratory syndrome coronavirus 2
- Coronaviridae
- Severe acute respiratory syndrome-related coronavirus
- unidentified influenza virus
- Middle East respiratory syndrome-related coronavirus
- H1N1 subtype
- Homo sapiens
- Mus musculus
- Mustela putorius furo
organisms_ner:
- Mus musculus
- Mustela putorius furo
- Homo sapiens
- Danio rerio
pmcid: PMC8576142
filename: gr3_lrg.jpg
figlink: /pmc/articles/PMC8576142/figure/fig0015/
number: F3
caption: 'Potential immunotherapies for COVID-19 by targeting various pathways in
  dysregulated myeloid cells to restore immune homeostasis. These immunotherapies
  may include: 1) blocking spike-myeloid receptor interaction; 2) inhibiting TLR signaling
  pathways; 3) engaging Siglec-10/G by CD24-Fc fusion protein or exosome to suppress
  DAMP signaling; 4) blocking JAK signaling pathway; 5) enhancing RIG-I or STING mediated
  production of IFNs; and 6) blocking myeloid cell-released proinflammatory cytokines,
  chemokines, and DAMPs.'
papertitle: Myeloid dysregulation and therapeutic intervention in COVID-19.
reftext: Runxia Gu, et al. Semin Immunol. 2021 Jun;55:101524-101524.
year: '2021'
doi: 10.1016/j.smim.2021.101524
journal_title: Seminars in Immunology
journal_nlm_ta: Semin Immunol
publisher_name: Elsevier Ltd.
keywords: COVID-19 | SARS-CoV-2 | Pathogenesis | Immunopathology | Myeloid cell |
  Hyperactivation | Immunotherapy
automl_pathway: 0.9509395
figid_alias: PMC8576142__F3
figtype: Figure
redirect_from: /figures/PMC8576142__F3
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8576142__gr3_lrg.html
  '@type': Dataset
  description: 'Potential immunotherapies for COVID-19 by targeting various pathways
    in dysregulated myeloid cells to restore immune homeostasis. These immunotherapies
    may include: 1) blocking spike-myeloid receptor interaction; 2) inhibiting TLR
    signaling pathways; 3) engaging Siglec-10/G by CD24-Fc fusion protein or exosome
    to suppress DAMP signaling; 4) blocking JAK signaling pathway; 5) enhancing RIG-I
    or STING mediated production of IFNs; and 6) blocking myeloid cell-released proinflammatory
    cytokines, chemokines, and DAMPs.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Siglecg
  - Tlr8
  - Tlr7
  - Myd88
  - Tlr4
  - Rigi
  - Sting1
  - Il6
  - Tnf
  - Csf2
  - Ccl3
  - Cxcl15
  - Il1
  - Cxcl10
  - Ccl2
  - TLR8
  - TLR7
  - MYD88
  - TLR4
  - RIGI
  - IL6
  - TNF
  - CXCL8
  - CXCL10
  - CXCL11
  - CXCL12
  - CXCL13
  - CXCL14
  - CXCL9
  - PF4
  - CXCL1
  - CXCL2
  - CXCL3
  - CXCL5
  - CXCL6
  - PPBP
  - SIGLEC10
  - TLR1
  - TLR2
  - TLR3
  - TLR5
  - TLR6
  - TLR9
  - TLR10
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - STING1
  - IFNA1
  - CSF2
  - CCL3
  - IL1B
  - CCL2
  - kita
  - ngfra
  - tlr7
  - myd88
  - rigi
  - ifnphi1
  - il6
  - tnfa
  - tnfb
  - cxcl8a
  - ccl38a.5
---
